Advertisement

The Drug Shortage Crisis in the United States: Impact on Cancer Pharmaceutical Safety

  • Narissa J. NonzeeEmail author
  • Thanh Ha Luu
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 171)

Abstract

Drug shortages pose a significant public health concern in the United States, and cancer drugs are among those most affected. Shortages present serious safety risks for patients and substantial burden on providers and the healthcare system. Multifaceted drivers of this complex problem include manufacturing disruptions, raw material shortages, regulatory issues, market dynamics, and limited financial incentives that reward quality and production of off-patent drugs. Oncology drugs in short supply have resulted in substitution of less effective or more toxic alternatives, medication errors, and treatment delays, and are especially concerning for medications with no adequate substitute. Consequently, patient outcomes such as disease progression and survival have been adversely affected. Furthermore, emerging gray markets have contributed to cost-prohibitive markups and introduction of counterfeit products that compromise patient safety. The Food and Drug Administration plays a key role in preventing and managing pharmaceutical shortages, largely through regulations requiring early notification of manufacturing interruptions. Other proposed strategies similarly target upstream causes and center on reducing regulatory hurdles for manufacturers and increasing incentives for market entry and quality improvement. Despite progress in preventing supply disruptions, continued exploration of underlying systemic drivers remains critical to informing long-term solutions and alleviating the clinical and economic impact of drug shortages.

Keywords

Drug shortage Cancer Drug substitution Pharmaceutical safety 

References

  1. 1.
    Fox ER (2015) National drug shortages: annual new shortages by year. 2015. Available from: http://www.ashp.org/DocLibrary/Policy/DrugShortages/Drug-Shortages-Statistics.pdf.
  2. 2.
    Jensen V, Rappaport BA. The reality of drug shortages—the case of the injectable agent propofol. N Engl J Med. 2010;363(9):806–7.CrossRefGoogle Scholar
  3. 3.
    Link MP, Hagerty K, Kantarjian HM. Chemotherapy drug shortages in the United States: genesis and potential solutions. J Clin Oncol. 2012;30(7):692–4.CrossRefGoogle Scholar
  4. 4.
    American Cancer Society, Cancer Facts & Figures 2016. 2016, American Cancer Society: Atlanta, GA.Google Scholar
  5. 5.
    Halpern MT, Yabroff KR. Prevalence of outpatient cancer treatment in the United States: estimates from the Medical Panel Expenditures Survey (MEPS). Cancer Invest. 2008;26(6):647–51.CrossRefGoogle Scholar
  6. 6.
    Chen SI, et al. Despite federal legislation, shortages of drugs used in acute care settings remain persistent and prolonged. Health Aff (Millwood). 2016;35(5):798–804.CrossRefGoogle Scholar
  7. 7.
    Baumer AM, et al. National survey of the impact of drug shortages in acute care hospitals. Am J Health Syst Pharm. 2004;61(19):2015–22.PubMedGoogle Scholar
  8. 8.
    Kaakeh R, et al. Impact of drug shortages on U.S. health systems. Am J Health Syst Pharm. 2011;68(19):1811–9.CrossRefGoogle Scholar
  9. 9.
    U.S. Food and Drug Administration. Strategic plan for preventing and mitigating drug shortages. 2013, U.S. Food and Drug Administration: Rockville, MD.Google Scholar
  10. 10.
    Woodcock J, Wosinska M. Economic and technological drivers of generic sterile injectable drug shortages. Clin Pharmacol Ther. 2013;93(2):170–6.PubMedGoogle Scholar
  11. 11.
    U.S. Food and Drug Administration. Guidance for industry: Sterile drug products produced by aseptic processing—current good manufacturing practice. 2004. Available from http://www.gmp-compliance.org/guidemgr/files/ASEPT_PROCESS_5882FNL.PDF.
  12. 12.
    Fox ER, et al. ASHP guidelines on managing drug product shortages in hospitals and health systems. Am J Health Syst Pharm. 2009;66(15):1399–406.CrossRefGoogle Scholar
  13. 13.
    Cherici C, McGinnis P, Russell W. Buyer beware: drug shortages and the gray market. Charlotte (NC) Premier Healthcare Alliance, 2011.Google Scholar
  14. 14.
    Provisional observations on drug product shortages: effects, causes, and potential solutions. Am J Health Syst Pharm. 2002; 59(22):2173–82.Google Scholar
  15. 15.
    Ventola CL. The drug shortage crisis in the United States: causes, impact, and management strategies. Pharm Ther 2011; 36(11):740–57.Google Scholar
  16. 16.
    Gu A, et al. Drug shortages in the US-causes, impact, and strategies. Innovations Pharm. 2011;2(4):6.CrossRefGoogle Scholar
  17. 17.
    Shortages of cancer drugs in the USA. Lancet Oncol. 2011; 12(4):313.Google Scholar
  18. 18.
    Gatesman ML, Smith TJ. The shortage of essential chemotherapy drugs in the United States. N Engl J Med. 2011;365(18):1653–5.CrossRefGoogle Scholar
  19. 19.
    Schweitzer SO. How the US Food and Drug Administration can solve the prescription drug shortage problem. Am J Public Health. 2013;103(5):e10–4.CrossRefGoogle Scholar
  20. 20.
    Krasomil E. Measuring the Impact of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 on shortages of sterile injectable oncology drugs. 2012.Google Scholar
  21. 21.
    U.S. Department of Health and Human Services Assistant Secretary for Planning and Evaluation. ASPE Issue Brief: Economic analysis of the causes of drug shortages. 2011; Available from http://aspe.hhs.gov/sp/reports/2011/DrugShortages/ib.shtml.
  22. 22.
    American Society of Health-System Pharmacists. 2014 Drug Shortage Summit 2014; Available from http://www.ismp.org/pressroom/2014-Drug-Shortages-Summit.pdf.
  23. 23.
    Yurukoglu A. Medicare reimbursements and shortages of sterile injectable pharmaceuticals. NBER Working Paper, 2012 (w17987).Google Scholar
  24. 24.
    Gottlieb S. Statement before the Committee on Oversight and Government Reform Subcommittee on Healthcare: The Causes of Drug Shortages and Proposals for Repairing these Market. 2011, American Enterprise Institute: Washington, DC.Google Scholar
  25. 25.
    U.S. House of Representatives Committee on Oversight and Government Reform, FDA’s Contribution to the Drug Shortage Crisis. 2012: Washington, DC.Google Scholar
  26. 26.
    Jacobson M, et al. How Medicare’s payment cuts for cancer chemotherapy drugs changed patterns of treatment. Health Aff 2010; 29(7):1391–1399.  https://doi.org/10.1377/hlthaff. 2009.
  27. 27.
    Jacobson M, et al. Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff (Millwood). 2006;25(2):437–43.CrossRefGoogle Scholar
  28. 28.
    Rider AE, et al. Clinical dilemmas and a review of strategies to manage drug shortages. J Pharm Pract. 2013;26(3):183–91.CrossRefGoogle Scholar
  29. 29.
    Goldsack JC, et al. Impact of shortages of injectable oncology drugs on patient care. Am J Health Syst Pharm. 2014;71(7):571–8.CrossRefGoogle Scholar
  30. 30.
    McBride A, et al. National survey on the effect of oncology drug shortages on cancer care. Am J Health Syst Pharm. 2013;70(7):609–17.CrossRefGoogle Scholar
  31. 31.
    Parsons HM, et al. Association between the number of suppliers for critical antineoplastics and drug shortages: implications for future drug shortages and treatment. J Oncol Pract. 2016; 12(3):e289–98, 249–50.Google Scholar
  32. 32.
    de Lemos ML, Waignein S, de Haan M. Evidence-based practice in times of drug shortage. J Oncol Pharm Pract. 2016;22(3):566–70.CrossRefGoogle Scholar
  33. 33.
    Gogineni K, Shuman KL, Emanuel EJ. Survey of oncologists about shortages of cancer drugs. N Engl J Med. 2013;369(25):2463–4.CrossRefGoogle Scholar
  34. 34.
    The state of cancer care in America. 2015: a report by the american society of clinical oncology. J Oncol Pract. 2015;11(2):79–113.CrossRefGoogle Scholar
  35. 35.
    Patel S, et al. A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia. Leuk Lymphoma. 2013;54(10):2231–5.CrossRefGoogle Scholar
  36. 36.
    Metzger ML, Billett A, Link MP. The impact of drug shortages on children with cancer—the example of mechlorethamine. N Engl J Med. 2012;367(26):2461–3.CrossRefGoogle Scholar
  37. 37.
    Kehl KL, et al. Oncologists’ experiences with drug shortages. J Oncol Pract. 2015;11(2):e154–62.CrossRefGoogle Scholar
  38. 38.
    Larkin H. Drug shortage may be worst in 30 years. Hosp Health Netw. 2011; 85(2):28–30, 32.Google Scholar
  39. 39.
    Nickel RS, et al. Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma. Pediatr Blood Cancer. 2014;61(5):810–4.CrossRefGoogle Scholar
  40. 40.
    Cassidy J, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26(12):2006–12.CrossRefGoogle Scholar
  41. 41.
    Smith JA, et al. Is it equivalent? Evaluation of the clinical activity of single agent Lipodox(R) compared to single agent Doxil(R) in ovarian cancer treatment. J Oncol Pharm Pract. 2016;22(4):599–604.CrossRefGoogle Scholar
  42. 42.
    Institute for Safe Medication Practice. Gray Market, Black Heart: Pharmaceutical Gray Market Finds a Disturbing Niche During the Drug Shortage Crisis. ISMP Medication Safety Alert! 2011. Available from https://www.ismp.org/resources/gray-market-black-heart-pharmaceutical-gray-market-finds-disturbing-niche-during-drug
  43. 43.
    McLaughlin M, et al. Effects on patient care caused by drug shortages: a survey. J Manag Care Pharm. 2013;19(9):783–8.PubMedGoogle Scholar
  44. 44.
    Biagi JJ, et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA. 2011;305(22):2335–42.CrossRefGoogle Scholar
  45. 45.
    Goozner M. Drug shortages delay cancer clinical trials. J Natl Cancer Inst. 2012.Google Scholar
  46. 46.
    Coalition of Cancer Cooperative Group. Fact sheet: drug shortages impacting cancer clinical trials. 2011. Available from http://www.cancertrialshelp.org/news_content/cancer_drug_shortages_fact_sheet.aspx.
  47. 47.
    Mackey TK, Liang BA. Oncology and the Internet: regulatory failure and reform. J Oncol Pract. 2012;8(6):341–3.CrossRefGoogle Scholar
  48. 48.
    U.S. Food and Drug Administration. Third annual report on drug shortages for calendar year 2015. 2015, U.S. Food and Drug Administration: Rockville, MD.Google Scholar
  49. 49.
    U.S. Food and Drug Administration. Pharmaceutical quality/manufacturing standards (cGMP). 2016. Available from http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064971.htm.
  50. 50.
    Born K. Time and money: an analysis of the legislative efforts to address the prescription drug shortage crisis in America. J Leg Med. 2012;33(2):235–51.CrossRefGoogle Scholar
  51. 51.
    Elzawawy A. The shortage of essential cancer drugs and generics in the United States of America: global brain storming directions for the world. Int J Cancer Clin Res. 2015;2:016.CrossRefGoogle Scholar
  52. 52.
    Jenks S. Efforts underway to curb drug shortages. J Natl Cancer Inst. 2011;103(12):914–5.CrossRefGoogle Scholar
  53. 53.
    American Society of Health-System Pharmacists. 2013 drug shortages summit: evaluating long-term solutions. 2013. Available from http://www.ashp.org/doclibrary/policy/drugshortages/april-2013-drug-shortages-summit-report-evaluating-long-term-solutions.pdf.
  54. 54.
    U.S. Government Accountability Office. Report to congressional addressees. Drug shortages: public health threat continues, despite efforts to help ensure product availability. Washington, D.C. 2014.Google Scholar
  55. 55.
    Brennan B. More competition: senator proposes priority reviews for some generics, new voucher program. 2016. Available from http://www.raps.org/Regulatory-Focus/News/2016/03/03/24466/More-Competition-Senator-Proposes-New-Priority-Reviews-for-Some-Generics-New-Voucher-Program/.
  56. 56.
    U.S. Food and Drug Administration. Generic drug user fee-abbreviated new drug application, prior approval supplement, drug master file, final dosage form facility, and active pharmaceutical ingredient facility fee rates for Fiscal Year 2015. 2014. Available from http://www.federalregister.gov/articles/2014/08/01/2014-18108/generic-drug-user-fee-abbreviated-new-drug-application-prior-approval-supplement-drug-master-file.
  57. 57.
    Neubauer MA, et al. Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting. J Oncol Pract. 2010;6(1):12–8.CrossRefGoogle Scholar
  58. 58.
    Zon RT, et al. American society of clinical oncology policy statement on clinical pathways in oncology. J Oncol Pract. 2016;12(3):261–6.CrossRefGoogle Scholar
  59. 59.
    Chabner BA. Drug shortages—a critical challenge for the generic-drug market. N Engl J Med. 2011;365(23):2147–9.CrossRefGoogle Scholar
  60. 60.
    Jones GH, et al. Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. Blood. 2016;127(11):1398–402.CrossRefGoogle Scholar
  61. 61.
    Vogel WH, Ervin RS. Oncology drug shortages in America. J Adv Pract Oncol. 2012;3(2):96–102.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Valgus J, et al. Ethical challenges: managing oncology drug shortages. J Oncol Pract. 2013;9(2):e21–3.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Health Policy and ManagementUniversity of CaliforniaLos AngelesUSA
  2. 2.University of Colorado DenverDenverUSA

Personalised recommendations